Preprint: Please note that this article has not completed peer review.
Research article

Clinicopathological profiling of small heterodimer partner, as a negative regulator of inflammatory responses in rectal cancer patients

Sup Kim, MiNa Joo, Min-Kyung Yeo, Moon-June Cho, Jun-Sang Kim, Eun-Kyeong Jo, Jin-Man Kim

Abstract

Background: Small heterodimer partner (SHP) is an orphan nuclear receptor family member that plays an essential role in the regulation of innate immune and inflammatory responses. However, the expression of SHP in rectal cancer and its prognostic significance have not been investigated. The aim of this study was to identify whether SHP levels are associated with cancer-related inflammation, treatment response and prognosis in rectal cancer patients. Methods: First, we performed classic gene set enrichment analysis (GSEA) to detect the association between high and low SHP expression using TCGA data sets. Then, the correlation between the expression of SHP and the prognosis of rectal cancer patients was evaluated using online OncoLnc database. Finally, we performed immunohistochemistry and analysed the correlation between SHP expression and clinicopathological / haematolgic features or treatment response of rectal cancer patients treated with radiochemotherapy. Results: Bioinformatics analysis indicated that low SHP mRNA expression was significantly associated with inflammatory response (NES = -1.67507) and poor prognosis (p = 0.0319). Nuclear expression of SHP was associated with cN stage (p = 0.003), Neutrophil (p = 0.023), Lymphocyte (p = 0.024), NLR (p = 0.023) and complete pathologic response after radiochemotherapy (p = 0.031). Low nuclear expression of SHP was associated with poor overall and distant metastasis-free survival for rectal cancer (p = 0.029 and p = 0.008) and retained significance as an independent prognostic factor for rectal cancer (p = 0.087 and p = 0.037). Conclusions: These results inidcate that SHP may act as an antiinflammatory mediator by regulating systemic and local immune responses in rectal cancer. Moreover, SHP might be used a candidate markers or therapeutic target in rectal cancer.

Keywords
Rectal cancer, Small heterodimer partner, Cancer-related inflammation, Radiochemotherapy, Prognosis

Figures

Background

Methods

Results

Discussion

Abbreviations

Declarations

References

Tables

Comments (0)

Comments can take the form of short reviews, notes or questions to the author. Comments will be posted immediately, but removed and moderated if flagged.

Learn more about our company.

Preprint: Please note that this article has not completed peer review.
Research article

Clinicopathological profiling of small heterodimer partner, as a negative regulator of inflammatory responses in rectal cancer patients

Sup Kim, MiNa Joo, Min-Kyung Yeo, Moon-June Cho, Jun-Sang Kim, Eun-Kyeong Jo, Jin-Man Kim

STATUS: In Review

Comments: 0
PDF Downloads: 0
HTML Views: 4

Integrity Check:

  • Article

  • Peer Review Timeline

  • Related Articles

  • Comments

Abstract

Background: Small heterodimer partner (SHP) is an orphan nuclear receptor family member that plays an essential role in the regulation of innate immune and inflammatory responses. However, the expression of SHP in rectal cancer and its prognostic significance have not been investigated. The aim of this study was to identify whether SHP levels are associated with cancer-related inflammation, treatment response and prognosis in rectal cancer patients. Methods: First, we performed classic gene set enrichment analysis (GSEA) to detect the association between high and low SHP expression using TCGA data sets. Then, the correlation between the expression of SHP and the prognosis of rectal cancer patients was evaluated using online OncoLnc database. Finally, we performed immunohistochemistry and analysed the correlation between SHP expression and clinicopathological / haematolgic features or treatment response of rectal cancer patients treated with radiochemotherapy. Results: Bioinformatics analysis indicated that low SHP mRNA expression was significantly associated with inflammatory response (NES = -1.67507) and poor prognosis (p = 0.0319). Nuclear expression of SHP was associated with cN stage (p = 0.003), Neutrophil (p = 0.023), Lymphocyte (p = 0.024), NLR (p = 0.023) and complete pathologic response after radiochemotherapy (p = 0.031). Low nuclear expression of SHP was associated with poor overall and distant metastasis-free survival for rectal cancer (p = 0.029 and p = 0.008) and retained significance as an independent prognostic factor for rectal cancer (p = 0.087 and p = 0.037). Conclusions: These results inidcate that SHP may act as an antiinflammatory mediator by regulating systemic and local immune responses in rectal cancer. Moreover, SHP might be used a candidate markers or therapeutic target in rectal cancer.

Figures

Background

Methods

Results

Discussion

Abbreviations

Declarations

References

Tables

Learn more about our company.